Structure Therapeutics (GPCR) Projected to Post Earnings on Thursday

Structure Therapeutics (NASDAQ:GPCR) is anticipated to post its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Structure Therapeutics to post earnings of ($0.35) per share for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, February 27, 2026 at 4:00 PM ET.

Structure Therapeutics Trading Down 4.3%

Shares of NASDAQ GPCR opened at $68.36 on Thursday. The company has a 50 day simple moving average of $75.09 and a two-hundred day simple moving average of $44.32. The stock has a market cap of $4.15 billion, a price-to-earnings ratio of -56.03 and a beta of -2.06. Structure Therapeutics has a 12 month low of $13.22 and a 12 month high of $94.90.

Institutional Trading of Structure Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. XTX Topco Ltd purchased a new position in shares of Structure Therapeutics during the 4th quarter valued at approximately $1,335,000. Voloridge Investment Management LLC purchased a new stake in Structure Therapeutics in the 4th quarter worth $17,388,000. Vestal Point Capital LP acquired a new position in Structure Therapeutics during the fourth quarter worth $2,434,000. Wellington Management Group LLP raised its position in Structure Therapeutics by 25.2% during the fourth quarter. Wellington Management Group LLP now owns 7,121,984 shares of the company’s stock worth $495,334,000 after acquiring an additional 1,432,797 shares during the period. Finally, SummitTX Capital L.P. purchased a new position in Structure Therapeutics during the fourth quarter valued at $6,584,000. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

GPCR has been the subject of a number of research reports. Stifel Nicolaus boosted their target price on shares of Structure Therapeutics from $50.00 to $90.00 and gave the company a “buy” rating in a research report on Monday, December 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Structure Therapeutics in a report on Thursday, January 22nd. Guggenheim raised their target price on Structure Therapeutics from $90.00 to $140.00 and gave the stock a “buy” rating in a report on Tuesday, January 20th. Citizens Jmp boosted their price target on Structure Therapeutics from $87.00 to $120.00 and gave the company a “market outperform” rating in a report on Friday, December 12th. Finally, The Goldman Sachs Group upgraded Structure Therapeutics to a “strong-buy” rating in a research report on Tuesday, January 20th. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $106.20.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.